// App-Quantinova.ai

9020 : Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.

Researchers

Presenter

  • Martin Reck

Principal Investigators

  • Matthew David Hellmann

  • Luis G. Paz-Ares

  • Suresh S. Ramalingam

  • Julie R. Brahmer

  • Kenneth John O'Byrne

  • Prabhu Bhagavatheeswaran

  • Faith Ellen Nathan

  • Hossein Borghaei

Medical Centers

  • LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Princess Alexandra Hospital, Moorooka, Queensland, Australia

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Fox Chase Cancer Center, Philadelphia, PA

Locations

  • United States

  • Germany

  • Spain

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02477826

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved